ETON Eton Pharmaceuticals, Inc.

Nasdaq etonpharma.com


$ 18.11 $ -0.16 (-0.87 %)    

Friday, 17-Oct-2025 15:59:59 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 18.18
$ 18.12
$ 17.50 x 30
$ 21.05 x 37
$ 17.91 - $ 18.80
$ 7.58 - $ 23.00
308,316
na
487.54M
$ 1.03
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-07-2025 06-30-2025 10-Q
2 05-13-2025 03-31-2025 10-Q
3 03-18-2025 12-31-2024 10-K
4 11-12-2024 09-30-2024 10-Q
5 08-08-2024 06-30-2024 10-Q
6 05-09-2024 03-31-2024 10-Q
7 03-14-2024 12-31-2023 10-K
8 11-09-2023 09-30-2023 10-Q
9 08-10-2023 06-30-2023 10-Q
10 05-11-2023 03-31-2023 10-Q
11 03-16-2023 12-31-2022 10-K
12 11-10-2022 09-30-2022 10-Q
13 08-11-2022 06-30-2022 10-Q
14 05-12-2022 03-31-2022 10-Q
15 03-16-2022 12-31-2021 10-K
16 11-16-2021 09-30-2021 10-Q
17 08-16-2021 06-30-2021 10-Q
18 05-13-2021 03-31-2021 10-Q
19 03-16-2021 12-31-2020 10-K
20 11-12-2020 09-30-2020 10-Q
21 08-12-2020 06-30-2020 10-Q
22 05-14-2020 03-31-2020 10-Q
23 03-05-2020 12-31-2019 10-K
24 11-14-2019 09-30-2019 10-Q
25 08-06-2019 06-30-2019 10-Q
26 05-07-2019 03-31-2019 10-Q
27 03-25-2019 12-31-2018 10-K
28 12-20-2018 09-30-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 eton-pharmaceuticals-q2-adj-eps-010-misses-005-estimate-sales-1893m-beat-1660m-estimate

Eton Pharmaceuticals (NASDAQ:ETON) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate o...

 the-fda-has-accepted-eton-pharmaceuticals-new-drug-application-for-et-600-a-proprietary-patented-formulation-of-desmopressin-oral-solution-for-review-and-assigned-a-prescription-drug-user-fee-act-target-action-date-of-february-25-2026

ET-600 is a proprietary formulation of desmopressin oral solution developed for the treatment of central diabetes insipidius, a...

 fda-approves-eton-pharmas-oral-drug-for-adrenal-insufficiency-in-pediatric-patients-analyst-sees-boost-in-2025-revenue

Eton Pharma's Khindivi has won FDA approval as a pediatric adrenal insufficiency treatment. It is projected to surge in sal...

 hc-wainwright--co-maintains-buy-on-eton-pharmaceuticals-raises-price-target-to-35

HC Wainwright & Co. analyst Swayampakula Ramakanth maintains Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises th...

 b-riley-securities-reiterates-buy-on-eton-pharmaceuticals-raises-price-target-to-26

B. Riley Securities analyst Madison El-Saadi reiterates Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises the price t...

 craig-hallum-maintains-buy-on-eton-pharmaceuticals-raises-price-target-to-28

Craig-Hallum analyst Chase Knickerbocker maintains Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises the price target...

 eton-pharmaceuticals-q1-adj-eps-007-beats-005-estimate-sales-1728m-beat-1513m-estimate

Eton Pharmaceuticals (NASDAQ:ETON) reported quarterly earnings of $0.07 per share which beat the analyst consensus estimate of ...

 eton-pharma-submits-nda-to-fda-for-proprietary-desmopressin-oral-solution-et-600-anticipates-q1-2026-launch-after-10-month-review

- NDA submitted for the treatment of central diabetes insipidus -- Expected 10-month review; commercial preparations underway f...

 craig-hallum-maintains-buy-on-eton-pharmaceuticals-raises-price-target-to-26

Craig-Hallum analyst Chase Knickerbocker maintains Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises the price target...

 b-riley-securities-reiterates-buy-on-eton-pharmaceuticals-raises-price-target-to-24

B. Riley Securities analyst Madison El-Saadi reiterates Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and raises the price t...

 hc-wainwright--co-reiterates-buy-on-eton-pharmaceuticals-maintains-33-price-target

HC Wainwright & Co. analyst Swayampakula Ramakanth reiterates Eton Pharmaceuticals (NASDAQ:ETON) with a Buy and maintain...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION